JP2022550828A5 - - Google Patents

Info

Publication number
JP2022550828A5
JP2022550828A5 JP2022520291A JP2022520291A JP2022550828A5 JP 2022550828 A5 JP2022550828 A5 JP 2022550828A5 JP 2022520291 A JP2022520291 A JP 2022520291A JP 2022520291 A JP2022520291 A JP 2022520291A JP 2022550828 A5 JP2022550828 A5 JP 2022550828A5
Authority
JP
Japan
Application number
JP2022520291A
Other languages
Japanese (ja)
Other versions
JP2022550828A (ja
JP7791083B2 (ja
JPWO2021064618A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2020/059185 external-priority patent/WO2021064618A1/en
Publication of JP2022550828A publication Critical patent/JP2022550828A/ja
Publication of JP2022550828A5 publication Critical patent/JP2022550828A5/ja
Publication of JPWO2021064618A5 publication Critical patent/JPWO2021064618A5/ja
Application granted granted Critical
Publication of JP7791083B2 publication Critical patent/JP7791083B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022520291A 2019-10-01 2020-10-01 カボテグラビルおよびリルピビリンでhivを治療するための方法 Active JP7791083B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201962908882P 2019-10-01 2019-10-01
US201962908995P 2019-10-01 2019-10-01
US62/908,995 2019-10-01
US62/908,882 2019-10-01
US202063037782P 2020-06-11 2020-06-11
US63/037,782 2020-06-11
US202063052214P 2020-07-15 2020-07-15
US63/052,214 2020-07-15
PCT/IB2020/059185 WO2021064618A1 (en) 2019-10-01 2020-10-01 Method for treating hiv with cabotegravir and rilpivirine

Publications (4)

Publication Number Publication Date
JP2022550828A JP2022550828A (ja) 2022-12-05
JP2022550828A5 true JP2022550828A5 (https=) 2023-10-12
JPWO2021064618A5 JPWO2021064618A5 (https=) 2023-10-12
JP7791083B2 JP7791083B2 (ja) 2025-12-23

Family

ID=72826936

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022520291A Active JP7791083B2 (ja) 2019-10-01 2020-10-01 カボテグラビルおよびリルピビリンでhivを治療するための方法

Country Status (11)

Country Link
US (3) US20220347174A1 (https=)
EP (1) EP4037661A1 (https=)
JP (1) JP7791083B2 (https=)
KR (1) KR20220074880A (https=)
CN (2) CN118416069A (https=)
AU (1) AU2020358156B2 (https=)
CA (1) CA3155587A1 (https=)
CL (1) CL2022000790A1 (https=)
IL (1) IL290716A (https=)
MX (1) MX2022003945A (https=)
WO (1) WO2021064618A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120053445A (zh) 2018-07-16 2025-05-30 吉利德科学公司 用于治疗hiv的衣壳抑制剂
WO2023222754A1 (en) * 2022-05-17 2023-11-23 Janssen Sciences Ireland Unlimited Company Rilpivirine for use in the treatment or prevention of hiv infection
WO2023222755A1 (en) * 2022-05-17 2023-11-23 Janssen Sciences Ireland Unlimited Company Treatment or prevention of hiv infection

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2480220T3 (pl) * 2009-09-22 2015-10-30 Janssen Sciences Ireland Uc Leczenie i zapobieganie zakażeniu HIV
KR20200031658A (ko) * 2017-07-21 2020-03-24 비이브 헬쓰케어 컴퍼니 Hib 감염 및 aids를 치료하기 위한 요법
CN109568328A (zh) * 2017-09-29 2019-04-05 重庆药友制药有限责任公司 一种用于预防和治疗hiv感染的药物组合物
LT3986561T (lt) * 2019-06-19 2024-04-25 VIIV Healthcare UK (No.5) Limited Pirido[2,3-d]pirimidino dariniai kaip žmogaus imunodeficito viruso replikacijos inhibitoriai

Similar Documents

Publication Publication Date Title
JP2022550828A5 (https=)
CN306948732S (https=)
CN306808178S (https=)
CN305615849S (https=)
CN306516335S (https=)
CN306352374S (https=)
CN306344466S (https=)
CN305615076S (https=)
CN306342051S (https=)
CN305611095S (https=)
CN306341072S (https=)
CN306325108S (https=)
CN306325107S (https=)
CN305603408S (https=)
CN306321227S (https=)
CN306302825S (https=)
CN306302546S (https=)
CN306296657S (https=)
CN305536329S (https=)
CN305534874S (https=)
CN305533518S (https=)
CN305533038S (https=)
CN305653247S (https=)
CN305531854S (https=)
CN305531609S (https=)